TABLE 2.
RRV isolation and flow cytometric analysis of lymphocyte subpopulations obtained by immunomagnetic bead depletiona
| Rhesus monkey no. | Fraction type | RRV serology | Positive cells (%)b
|
Virus isolationc | ||
|---|---|---|---|---|---|---|
| CD4+ | CD8+ | CD20+ | ||||
| 1 | Total PBMCs | Seronegative | 51 | 35 | 8.4 | − |
| T-cell enriched | 56 | 33 | 0 | − | ||
| B-lymphocyte enriched | 0 | 19 | 69 | − | ||
| 2 | Total PBMCs | Seropositive | 38 | 37 | 12 | − |
| T-cell enrichedd | 41 | 51 | 0 | − | ||
| B-cell enrichede | 16 | 19 | 75 | − | ||
| 3 | Total PBMCs | Seropositive | 43 | 38 | 27 | − |
| T-cell enriched | 47 | 43 | 12 | − | ||
| B-cell enriched | 0 | 0 | 50 | + | ||
| 4 | Total PBMCs | Seropositive | 26 | 49 | 37 | − |
| T-cell enriched | 19 | 59 | 12 | − | ||
| B-cell enriched | 2.8 | 5.0 | 80 | + | ||
| 5 | Total PBMCs | Seropositive | 41 | 28 | 24 | − |
| T-cell enriched | 47 | 35 | 15 | − | ||
| B-cell enriched | 0 | 12 | 86 | + | ||
Negative selection by immunomagnetic bead depletion was performed according to the manufacturer’s instructions (Coulter-Immunotech).
One hundred thousand cells from each fraction were separated into five aliquots and stained individually with monoclonal antibodies labeled with FITC—OKT4 (CD4), B9.11 (CD8), and B-Ly-1 (CD20)—and the appropriate isotypic negative control.
One hundred thousand cells from each fraction were cocultured with primary rhesus fibroblasts for virus isolation in triplicate. A positive virus isolation was scored when two of three wells developed cytopathic effects characteristic of RRV (6, 13) after 10 days and confirmed by indirect immunofluorescence with serum samples obtained from monkeys experimentally inoculated with RRV strain 17577.
The T-cell-enriched population was generated by depleting PBMCs with B-Ly-1-conjugated magnetic beads (CD20+ cells; Coulter-Immunotech).
The B-cell-enriched population was generated by depleting PBMCs with the magnetic beads conjugated with the monoclonal antibodies FN18 (CD3+ cells; generously provided by M. Jonker) and B9.11 (CD8+ cells; Coulter-Immunotech).